| __timestamp | Protagonist Therapeutics, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7459000 | 21263000 |
| Thursday, January 1, 2015 | 11831000 | 18890000 |
| Friday, January 1, 2016 | 25705000 | 15295000 |
| Sunday, January 1, 2017 | 46181000 | 12944000 |
| Monday, January 1, 2018 | 59497000 | 13599000 |
| Tuesday, January 1, 2019 | 65003000 | 30391000 |
| Wednesday, January 1, 2020 | 74506000 | 13020000 |
| Friday, January 1, 2021 | 126006000 | 16287000 |
| Saturday, January 1, 2022 | 126215000 | 19943000 |
| Sunday, January 1, 2023 | 120161000 | 21042000 |
Cracking the code
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Protagonist Therapeutics, Inc. and Vericel Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Protagonist Therapeutics has consistently increased its R&D expenses, peaking in 2022 with a staggering 1,262% increase from its 2014 spending. This upward trajectory underscores their aggressive pursuit of groundbreaking therapies. In contrast, Vericel Corporation's R&D spending has remained relatively stable, with a modest 10% increase over the same period. This conservative approach may reflect a focus on optimizing existing products rather than expanding their pipeline. As the biotech industry evolves, these spending patterns offer valuable insights into each company's strategic priorities and potential for future growth.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Bio-Techne Corporation and Protagonist Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Vericel Corporation
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Vericel Corporation vs MannKind Corporation
Analyzing R&D Budgets: Vericel Corporation vs Wave Life Sciences Ltd.
R&D Spending Showdown: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE